Angers

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Chronic myeloid leukaemia1 trial
• High blood pressure1 trial
• Multiple sclerosis1 trial
• Myeloproliferative neoplasms1 trial
• Pulmonary arterial hypertension1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 1/21 trial
• Phase 2/31 trial
• Phase 31 trial

Status

• Active, not recruiting2 trials
• Recruiting2 trials
• Completed1 trial
• Terminated1 trial

Lead sponsor

• Novartis Pharmaceuticals6 trials

Running trials

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  NCT06649110· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

  NCT06092879· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

  NCT06157086· Novartis Pharmaceuticals· Source

• Recruiting

  Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

  NCT05948943· Phase 2/3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• High blood pressure1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France

  NCT07839858· Novartis Pharmaceuticals· Source

• Terminated

  Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

  NCT04251533· Phase 3· Novartis Pharmaceuticals· Source